Related Experiment Video

Updated: Jun 20, 2026

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software
07:32

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Published on: April 12, 2024

JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma

Qingshan Chang1, Jianguo Chen, Kevin J Beezhold

  • 1Graduate Center for Toxicology, University of Kentucky, Lexington, KY40536, USA. qchan2@email.uky.edu

Molecular Cancer
|August 19, 2009
PubMed

Insights

Hepatocellular carcinoma (HCC) with high JNK1 activation may originate from hepatic progenitor cells, showing poor prognosis and metastasis. JNK1 activation status could serve as a novel biomarker for HCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hepatology

Background:

  • Hepatocellular carcinoma (HCC) is a prevalent cancer with a poor prognosis.
  • Current molecular classification of HCC is not well-established.

Purpose of the Study:

  • To identify HCC molecular signatures based on JNK1 activation status.
  • To explore the potential of JNK1 as a prognostic biomarker in HCC.

Main Methods:

  • Gene expression profiling of 31 HCC specimens and matched noncancerous liver tissue.
  • Sub-grouping HCC based on high JNK1 (H-JNK1) and low JNK1 (L-JNK1) activation.
  • Analysis of signature genes, biomarker expression, and survival data.

Main Results:

  • Two distinct gene sets identified for H-JNK1 and L-JNK1 HCC.
  • H-JNK1 HCC showed overlap with hepatoblastoma signatures and over-expressed hepatic progenitor cell biomarkers (AFP, KRT19, etc.).
  • H-JNK1 HCC exhibited genes associated with metastasis and recurrence, with down-regulated normal liver function genes and impaired patient survival.

Conclusions:

  • H-JNK1 HCC may arise from hepatic progenitor cells, correlating with a poorer prognosis.
  • JNK1 activation status in HCC tissue represents a potential new biomarker for prognosis.
  • JNK1 status may offer a target for novel HCC therapeutic strategies.
Abstract

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...